Drug
Brensocatib clinical trials
Also written INS1007 and AZD7986.
- studies test it
- 14
- open now
- 1
- in phase 3
- 2
- first study started
- 2017
Keep track of what changes. Save the brensocatib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 8
- Phase 2
- 4
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 1
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses brensocatib is read from its arms, and is right about nine times in ten.
Testing it · 14
- A Study to Assess the Potential CYP3A Induction Effect of Brensocatib on the Pharmacokinetics (PK) of Midazolam in Healthy ParticipantsNot yet recruitingPhase 1Insmed IncorporatedNCT07859007Written as Brensocatib
- A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)CompletedPhase 2Insmed IncorporatedNCT06013241Written as Brensocatib
- A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)TerminatedPhase 2Insmed IncorporatedNCT06685835Written as Brensocatib
- A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic FibrosisCompletedPhase 2Insmed IncorporatedNCT05090904Written as Brensocatib
- A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis BronchiectasisCompletedPhase 3Insmed IncorporatedNCT04594369Written as Brensocatib 10 mg
- A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy ParticipantsCompletedPhase 1Insmed IncorporatedNCT06344728Written as Brensocatib Oral Solution
- A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy ParticipantsCompletedPhase 1Insmed IncorporatedNCT06178783Written as Brensocatib
- A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy ParticipantsCompletedPhase 1Insmed IncorporatedNCT05965570Written as Brensocatib
- STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19CompletedPhase 3University of DundeeNCT04817332Written as Brensocatib
- A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic ImpairmentCompletedPhase 1Insmed IncorporatedNCT05517525Written as Brensocatib
- A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of INS1007 in Healthy Japanese and Caucasian ParticipantsCompletedPhase 1Insmed IncorporatedNCT05927597Written as INS1007
- A Study of Brensocatib Following a Single Oral Administration in Participants With or Without Renal ImpairmentCompletedPhase 1Insmed IncorporatedNCT05673603Written as Brensocatib
- Assessment of INS1007 in Participants With Non-Cystic Fibrosis BronchiectasisCompletedPhase 2Insmed IncorporatedNCT03218917Written as Brensocatib 10 mg
- A Study of the Absorption, Metabolism, and Excretion of [14C]-Brensocatib Following a Single Oral Administration in Healthy Male ParticipantsCompletedPhase 1Insmed IncorporatedNCT05652257Written as [14C]-brensocatib
Given in every arm · 3 — brensocatib is usual care beside what is tested
- A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy ParticipantsCompletedPhase 1Insmed IncorporatedNCT05826574Written as Brensocatib
- A Study to Investigate the Effects of Brensocatib on QT Interval in Healthy ParticipantsCompletedPhase 1Insmed IncorporatedNCT05355935Written as Brensocatib
- A Phase I Study to Assess PK of AZD7986 Alone & With Verapamil, Itraconazole or Diltiazem in Healthy SubjectsCompletedPhase 1AstraZenecaNCT02653872Written as AZD7986
Codes
What other systems call brensocatib · ClinicalTrials.gg INT000695
- MeSH (NLM) C000619932brensocatibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 25CG88L0BBBRENSOCATIBConfirmed FDA, NLM, Wikidata
- Wikidata Q105334645brensocatibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C171778BrensocatibOne source FDA
- DrugBank DB15638One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000619932 | brensocatib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 25CG88L0BB | BRENSOCATIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q105334645 | brensocatib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C171778 | Brensocatib | One source FDA |
| DrugBank | DB15638 | — | One source Wikidata |
Also registered as brensocatib monohydrate (UNII PFW1O9NG45).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.